Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
2
Neutral
6
Bullish
6
Bearish
26
Neutral
6
Bullish
14
Bearish
24
Neutral
0
Bullish
8
Discovery themes featuring this stock
Inventurus Knowledge Solutions Limited (IKS Health) is a tech-enabled healthcare provider enablement platform that outsources and automates administrative and clinical workflows for US healthcare providers, spanning pre-visit, peri-visit and post-visit features across ambulatory and acute settings and serving hundreds of enterprise customers with a mix of people and AI-led solutions.
Q3 FY26 delivered strong operating performance: INR 8,150 million revenue (24% YoY), adjusted EBITDA margin near mid-30s and adjusted PAT growth near 48% YoY, reflecting faster-than-market revenue expansion and a margin-rich business model driven by AI-led automation and accelerated AQuity integration into consolidated results.
IKS has moved to an AI-native, agentic orchestration approach—launching Scribble Now, autonomous coding in select specialties and multi-agent workflows across patient access and documentation—demonstrating measurable non-linearity between revenue growth and headcount expansion, with headcount essentially flat versus substantial revenue uplift.
Strategically the business is shifting upstream to outcome-oriented economics via net economic value-add (NEVA) guarantees: the Palomar 15-year engagement (NEVA advance) generated $3 million in the first year, substantiating the company’s ability to monetize outcomes while preserving stickiness and opening a second pool of economics beyond usage fees.
Cash generation is robust and improving: OCF and FCF surged nearly 50% YoY in 9M FY26, net debt fell meaningfully to INR 3,220 million as of Dec 31, 2025, and management flagged continued prioritization of deleveraging, selective inorganic opportunities and reinvestment into R&D and go-to-market acceleration.
IT - Services
IT Enabled Services
24,785 Cr
Low Risk
35.2
27.4
1.4
11.1
1,875.25
1,226.15
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
3431.20 | 35,838 Cr | 28.94 | 5.54 | 1.18 | 19.76 | 24.25 | 12.21 | ||
1368.35 | 24,785 Cr | 35.21 | 11.06 | 0.00 | 27.21 | 27.85 | 18.39 | ||
566.30 | 23,110 Cr | 43.30 | 6.48 | 2.05 | 19.44 | 24.18 | 7.42 | ||
3225.70 | 21,823 Cr | 103.12 | 37.71 | 0.06 | 23.20 | 31.05 | 16.78 | ||
1418.55 | 19,814 Cr | 45.53 | 6.08 | 0.00 | 12.88 | 15.72 | 11.20 | ||
42.43 | 19,390 Cr | 23.44 | 2.18 | 0.00 | 8.98 | 11.63 | 7.37 | ||
527.00 | 9,699 Cr | 43.85 | 8.35 | 0.17 | 30.03 | 20.16 | 6.02 | ||
| Median: 7 Co. | — | 1368.35 | 21,823 Cr | 43.30 | 6.48 | 0.06 | 19.76 | 24.18 | 11.20 |
Inventurus Knowledge Solutions Ltd (IKS) is currently trading at 1,431.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Inventurus Knowledge Solutions Limited (IKS Health) is a tech-enabled healthcare provider enablement platform that outsources and automates administrative and clinical workflows for US healthcare providers, spanning pre-visit, peri-visit and post-visit features across ambulatory and acute settings and serving hundreds of enterprise customers with a mix of people and AI-led solutions. Q3 FY26 delivered strong operating performance: INR 8,150 million revenue (24% YoY), adjusted EBITDA margin near mid-30s and adjusted PAT growth near 48% YoY, reflecting faster-than-market revenue expansion and a margin-rich business model driven by AI-led automation and accelerated AQuity integration into consolidated results. IKS has moved to an AI-native, agentic orchestration approach—launching Scribble Now, autonomous coding in select specialties and multi-agent workflows across patient access and documentation—demonstrating measurable non-linearity between revenue growth and headcount expansion, with headcount essentially flat versus substantial revenue uplift. Strategically the business is shifting upstream to outcome-oriented economics via net economic value-add (NEVA) guarantees: the Palomar 15-year engagement (NEVA advance) generated $3 million in the first year, substantiating the company’s ability to monetize outcomes while preserving stickiness and opening a second pool of economics beyond usage fees. Cash generation is robust and improving: OCF and FCF surged nearly 50% YoY in 9M FY26, net debt fell meaningfully to INR 3,220 million as of Dec 31, 2025, and management flagged continued prioritization of deleveraging, selective inorganic opportunities and reinvestment into R&D and go-to-market acceleration.
Over the past 52 weeks, Inventurus Knowledge Solutions Ltd has traded between a low of ₹1,226.15 and a high of ₹1,875.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Inventurus Knowledge Solutions Ltd has a market capitalization of approximately 24,784.73. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Inventurus Knowledge Solutions Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 35.21 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 24,784.73 Cr, Inventurus Knowledge Solutions Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Inventurus Knowledge Solutions Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Inventurus Knowledge Solutions Ltd is 35.21. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Inventurus Knowledge Solutions, Inc. (IKS), the US subsidiary of Inventurus Knowledge Solutions Limited (IKS Health), is acquiring TruBridge. IKS Health is listed on NSE and BSE.
TruBridge shareholders will receive $26.25 in cash for each share of common stock under the merger agreement.
TruBridge shareholders will receive $26.25 in cash for each share of TruBridge common stock.
Inventurus Knowledge Solutions, Inc. (IKS), the US subsidiary of Inventurus Knowledge Solutions Limited (IKS Health), has signed a definitive agreement to acquire TruBridge, Inc.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Acquisition Agreement
IKS Health published investor FAQs on its agreement to acquire TruBridge, outlining strategic rationale—EHR integration with IKS’ AI care platform, cross‑sell whitespace (~$440M–$575M), expected cost synergies, tech diligence and clearinghouse benefits.
Acquisition/M&A
IKS Health (Inventurus Knowledge Solutions) agreed to acquire TruBridge for $26.25 per share in cash; the deal is board‑approved and expected to close in Q3 2026 subject to shareholder and regulatory approvals, HSR clearance, and debt financing.
Strategic acquisition
Inventurus Knowledge Solutions (IKS) announced agreement to acquire 100% of TruBridge, Inc., to take it private with ~US$600M debt financing (5‑yr term, SOFR+275–175bps), expected FY27 PAT/EPS accretive; proforma revenue ~$698M and adj. EBITDA ~26%.
Strategic acquisition
IKS proposes to acquire 100% of TruBridge (US-listed) and delist it, financed by ~USD 600M five‑year debt (SOFR+275bp sliding to +175bp); pro forma revenue ~$698M, adj. EBITDA 26%, expected EPS/PAT accretive in FY27.
Conference Call - Acquisition
IKS Health has scheduled a conference call with investors/analysts on Apr 24, 2026 at 08:30 IST to discuss its agreement to acquire TruBridge; dial‑in, international toll‑free numbers and webcast/registration links provided.
Strategic acquisition
IKS proposes to acquire 100% of TruBridge and take it private, funded by approx. $600M of debt (5‑yr, SOFR+275bps sliding to 175bps); proforma revenue ~$698M, adj. EBITDA ~26%, deal expected PAT/EPS accretive in FY27.
